This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maloney DG, Grillo-Lopez AJ, White CA, Bodkin DJ, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R . IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 1997 90: 2188–2195
Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles T-M, Royston I, Varns C, Rosemberg J, Levy R . IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed low-grade non-Hodgkin's lymphoma J Clin Oncol 1997 16: 3266–3274
McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK . Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825–2833
Feuring-Buske M, Buske C, Unterhalt M, Hiddemann W . Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma Ann Hematol 2000 79: 167–174
Hainsworth JD, Burris III HA, Morrisey LH, Litchy S, Scullin DC Jr, Bearden JD III, Richards P, Greco FA . Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma Blood 2000 95: 3052–3056
Winkler U, Jensen M, Manzke O, Shultz H, Diehl V, Engert A . Cytokine-release syndrome in patients with B cell chronic lymphocytic leukemia and high lymphocitic counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood 1999 94: 2217–2224
Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BR, Sipe MA, Donegan S, White CA . Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance J Clin Oncol 1999 17: 791–795
Lim LC, Koh LP, Tan P . Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with lymphocytic leukemia J Clin Oncol 1999 17: 1962–1963
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rigamonti, C., Volta, C., Colombi, S. et al. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. Leukemia 15, 186–187 (2001). https://doi.org/10.1038/sj.leu.2401987
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401987
This article is cited by
-
Rituximab-induced acute thrombocytopenia: a case report and review of the literature
Medical Oncology (2009)